A press release today from Galderma confirms that they will be marketing the product known in the US as Oracea under the name Apprilon in Canada.
Two million Canadians suffer from this chronic inflammatory skin disease; March is Rosacea Awareness Month
THORNHILL, ON, Feb. 27, 2013 /CNW/ – Galderma Canada Inc. today announced Apprilon, an innovative, anti-inflammatory rosacea treatment, is now available for prescription in Canada.
Apprilon (Doxycycline Modified-Release Capsule, 40 mg) is the first and only oral, once-daily therapy designed specifically to treat the bumps and pimples associated with rosacea, and does not cause complications associated with long-term antibiotic use.
Recent evidence suggests rosacea is primarily an inflammatory condition, not a bacterial infection. Apprilon is the only medication that reduces the inflammatory response in patients with rosacea without producing drug concentrations required to treat bacterial diseases.
Each Apprilon capsule contains two types of beads that together provide a dose of 40 mg of doxycycline, an antibiotic in the tetracycline family.
The immediate-release beads contain 30 mg of doxycycline and the delayed-release beads contain 10 mg of doxycycline.
Clinical studies show the combination of immediate and delayed-release beads keeps Apprilon at a very low dose that will not produce antibiotic resistance over the long term.
Marketed as Oracea in the United States, the availability of Apprilon in Canada reinforces Galderma’s commitment to providing novel skin care treatment options.
Apprilon is now available for prescription across Canada. Patients should speak with their family doctor or dermatologist to learn more about Apprilon and its suitability for their skincare needs.
Last month Rosacea News reported that Efracea had been approved for use in Canada, but now it is clear that the plan was to market this low dose antibiotic as Apprilon.
Oracea is marketed as Efracea in the UK and Europe.
- Efracea is the UK version of Oracea
- Oracea User Reviews
- Oracea is Not an Antibiotic, Apparently
- Oracea Too Expensive ?